Peter Annas

Author PubWeight™ 15.71^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.	J Clin Psychiatry	2009	2.09
2	Longitudinal stability of CSF biomarkers in Alzheimer's disease.	Neurosci Lett	2007	1.54
3	Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia.	Clin Exp Pharmacol Physiol	2012	1.42
4	A twin study of the genetics of fear conditioning.	Arch Gen Psychiatry	2003	1.30
5	Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.	J Alzheimers Dis	2009	1.06
6	A longitudinal twin study of fears from middle childhood to early adulthood: evidence for a developmentally dynamic genome.	Arch Gen Psychiatry	2008	0.99
7	Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia.	J Alzheimers Dis	2013	0.97
8	Effects of sleep or food deprivation during civilian survival training on cognition, blood glucose and 3-OH-butyrate.	Wilderness Environ Med	2011	0.93
9	Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.	J Alzheimers Dis	2013	0.83
10	The genetic covariation between fear conditioning and self-report fears.	Biol Psychiatry	2007	0.82
11	Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's disease.	J Alzheimers Dis	2012	0.81
12	Different genetic factors underlie fear conditioning and episodic memory.	Psychiatr Genet	2015	0.77
13	Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia.	Clin Exp Pharmacol Physiol	2013	0.77
14	Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease.	Curr Alzheimer Res	2011	0.77
15	Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials.	J Alzheimers Dis	2012	0.76